Redeye: Cellavision Q2’23 - Improving outlook
Redeye’s view on the Q2 report. The organic growth trend continues to be weak, although the situation has improved during the quarter. The deviation from our estimates was slight, but some uncertainties remain in the coming quarters. We have made minor changes to our estimates and slightly adjusted our Base case to SEK 230 (220) and fair value range to SEK 160 – 380 (155 – 380) per share.
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/